U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06885879) titled 'Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma' on March 14.
Brief Summary: Radiotherapy is increasingly being used in the management of hepatocellular carcinoma (HCC) as a standalone treatment, or in combination with systemic therapy. Stereotactic Body Radiation Therapy (SBRT) causes cell death both directly (via double-stranded breaks) and indirectly (via vascular bed damage or promotion of antitumour immunity). Unfortunately, the effect of cell death is not immediate and takes time. As a result, the typical arterial phase hyperenhancement on imaging may persist up to 12 months after radiotherapy, and i...